{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:01:22Z","timestamp":1788210082394,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Magnetic resonance-guided radiotherapy (MRgRT) utilization is rapidly expanding, driven by advanced capabilities including better soft tissue imaging, continuous intrafraction target visualization, automatic triggered beam delivery, and the availability of on-table adaptive replanning. Our objective was to describe patterns of 0.35 Tesla (T)-MRgRT utilization in Europe and Asia among early adopters of this novel technology.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Anonymized administrative data from all 0.35T-MRgRT treatment systems in Europe and Asia were extracted for patients who completed treatment from 2015 to 2020. Detailed treatment information was analyzed for all MR-linear accelerators (linac) and -cobalt systems.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From 2015 through the end of 2020, there were 5796 completed treatment courses delivered in 46,389 individual fractions. 23.5% of fractions were adapted. Ultra-hypofractionated (UHfx) dose schedules (1\u20135 fractions) were delivered for 63.5% of courses, with 57.8% of UHfx fractions adapted on-table. The most commonly treated tumor types were prostate (23.5%), liver (14.5%), lung (12.3%), pancreas (11.2%), and breast (8.0%), with increasing compound annual growth rates (CAGRs) in numbers of courses from 2015 through 2020 (pancreas: 157.1%; prostate: 120.9%; lung: 136.0%; liver: 134.2%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the first comprehensive study reporting patterns of utilization among early adopters of a 0.35T-MRgRT system in Europe and Asia. Intrafraction MR image-guidance, advanced motion management, and increasing adoption of on-table adaptive RT have accelerated a transition to UHfx regimens. MRgRT has been predominantly used to treat tumors in the upper abdomen, pelvis and lungs, and increasingly with adaptive replanning, which is a radical departure from legacy radiotherapy practices.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-022-02114-2","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T17:07:53Z","timestamp":1661188073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia"],"prefix":"10.1186","volume":"17","author":[{"given":"Berend J.","family":"Slotman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enis","family":"\u00d6zyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myungsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Itami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Tallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PierCarlo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Hama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Andratschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Camilleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Quivrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BoKyong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"van Overeem Felter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"2114_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2007.11.023","volume":"86","author":"D Verellen","year":"2008","unstructured":"Verellen D, De Ridder M, Storme G. A (short) history of image-guided radiotherapy. Radiother Oncol. 2008;86:4\u201313.","journal-title":"Radiother Oncol"},{"key":"2114_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejca.2019.07.021","volume":"122","author":"WA Hall","year":"2019","unstructured":"Hall WA, Paulson ES, van der Heide UA, Fuller CD, Raaymakers BW, Lagendijk JJW, et al. The transformation of radiation oncology using real-time magnetic resonance guidance: a review. Eur J Cancer. 2019;122:42\u201352.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2114_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/1754-9485.12968","volume":"64","author":"S Chin","year":"2020","unstructured":"Chin S, Eccles CL, McWilliam A, Chuter R, Walker E, Whitehurst P, et al. Magnetic resonance-guided radiation therapy: a review. J Med Imaging Radiat Oncol. 2020;64(1):163\u201377.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"3","key":"2114_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","volume":"126","author":"L Henke","year":"2018","unstructured":"Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradly J, et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol. 2018;126(3):519\u201326.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2114_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.adro.2018.10.003","volume":"4","author":"LE Henke","year":"2018","unstructured":"Henke LE, Olsen JR, Contreras JA, CurCuru A, DeWees TA, Green OL, et al. Stereotactic MR-guided online adaptive radiation therapy (SMART) for ultracentral thorax malignancies: results of a phase 1 trial. Adv Radiat Oncol. 2018;4(1):201\u20139.","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"2114_CR6","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.ijrobp.2019.08.007","volume":"105","author":"AME Bruynzeel","year":"2019","unstructured":"Bruynzeel AME, Tetar SU, Oei SS, Senan S, Haasbeek CJA, Spoelstra FOB, et al. A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: early toxicity results. Int J Radiat Oncol Biol Phys. 2019;105(5):1086\u201394.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2114_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.adro.2018.08.005","volume":"4","author":"SA Rosenberg","year":"2018","unstructured":"Rosenberg SA, Henke LE, Shaverdian N, Mittauer K, Wojcieszynski AP, Hullett CR. A multi-institutional experience of MR-guided liver stereotactic body radiation therapy. Adv Radiat Oncol. 2018;4(1):142\u20139.","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"2114_CR8","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/cam4.2100","volume":"8","author":"S Rudra","year":"2019","unstructured":"Rudra S, Jiang N, Rosenberg SA, Olsen JR, Roach MC, Wan L, et al. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Med. 2019;8(5):2123\u201332.","journal-title":"Cancer Med"},{"issue":"2","key":"2114_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ijrobp.2020.02.025","volume":"107","author":"T Finazzi","year":"2020","unstructured":"Finazzi T, Haasbeek CJA, Spoelstra FOB, Palacios MA, Admiraal MA, Bruynzeel AME, et al. Clinical outcomes of stereotactic MR-guided adaptive radiation therapy for high-risk lung tumors. Int J Radiat Oncol Biol Phys. 2020;107(2):270\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2114_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.phro.2020.05.002","volume":"14","author":"T Finazzi","year":"2020","unstructured":"Finazzi T, van S\u00f6rnsen de Koste JR, Palacios MA, Spoelstra FOB, Slotman BJ, Haasbeek CJA, Senan S. Delivery of magnetic resonance-guided single-fraction stereotactic lung radiotherapy. Phys Imaging Radiat Oncol. 2020;14:17\u201323.","journal-title":"Phys Imaging Radiat Oncol"},{"issue":"1","key":"2114_CR11","doi-asserted-by":"publisher","first-page":"100506","DOI":"10.1016\/j.adro.2020.06.010","volume":"6","author":"C Hassanzadeh","year":"2020","unstructured":"Hassanzadeh C, Rudra S, Bommireddy A, Hawkins WG, Wang-Gillam A, Fields RC, et al. Ablative five-fraction stereotactic body radiotherapy for inoperable pancreatic cancer using online MR-guided adaptation. Adv Radiat Oncol. 2020;6(1):100506.","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"2114_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijrobp.2020.02.021","volume":"107","author":"WR Kennedy","year":"2020","unstructured":"Kennedy WR, Thomas MA, Stanley JA, Luo J, Ochoa LL, Clifton KK, et al. Single-institution phase 1\/2 prospective clinical trial of single-fraction, high-gradient adjuvant partial-breast irradiation for hormone sensitive stage 0-I breast cancer. Int J Radiat Oncol Biol Phys. 2020;107(2):344\u201352.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2114_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.adro.2019.09.008","volume":"5","author":"E Luterstein","year":"2019","unstructured":"Luterstein E, Cao M, Lamb JM, Raldow A, Low D, Steinberg ML, Lee P. Clinical outcomes using magnetic resonance-guided stereotactic body radiation therapy in patients with locally advanced cholangiocarcinoma. Adv Radiat Oncol. 2019;5(2):189\u201395.","journal-title":"Adv Radiat Oncol"},{"issue":"10","key":"2114_CR14","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.3390\/cancers12102763","volume":"12","author":"SU Tetar","year":"2020","unstructured":"Tetar SU, Bohoudi O, Senan S, Palacios MA, Oei SS, van der Wel AM, et al. The role of daily adaptive stereotactic MR-guided radiotherapy for renal cell cancer. Cancers (Basel). 2020;12(10):2763.","journal-title":"Cancers (Basel)"},{"key":"2114_CR15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2020.05.007","volume":"4","author":"SU Tetar","year":"2020","unstructured":"Tetar SU, Bruynzeel AME, Oei SS, Senan S, Fraikin T, Slotman BJ, et al. Magnetic resonance-guided stereotactic radiotherapy for localized prostate cancer: final results on patient-reported outcomes of a prospective phase 2 study. Eur Urol Oncol. 2020;4:628\u201334.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"2114_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.prro.2020.09.005","volume":"11","author":"MD Chuong","year":"2021","unstructured":"Chuong MD, Bryant J, Mittauer KE, Hall M, Kotecha R, Alvarez D, et al. Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy with on-table adaptive replanning and elective irradiation for inoperable pancreas cancer. Pract Radiat Oncol. 2021;11(2):134\u201347.","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"2114_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3857\/roj.2020.00976","volume":"39","author":"G Ugurluer","year":"2021","unstructured":"Ugurluer G, Mustafayev TZ, Gunfor G, Atalar B, Abacioglu U, Sengoz M, et al. Stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic patients: initial experience. Radiat Oncol J. 2021;39(1):33\u201340.","journal-title":"Radiat Oncol J"},{"key":"2114_CR18","doi-asserted-by":"publisher","first-page":"20200696","DOI":"10.1259\/bjr.20200696","volume":"94","author":"G Ugurluer","year":"2021","unstructured":"Ugurluer G, Atalar B, Mustafayev TZ, Gungor G, Aydin G, Sengoz M, et al. Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity. Br J Radiol. 2021;94:20200696.","journal-title":"Br J Radiol"},{"issue":"21","key":"2114_CR19","first-page":"06577","volume":"S0167\u20138140","author":"R van Dams","year":"2021","unstructured":"van Dams R, Wu TC, Kishan AU, et al. Ablative radiotherapy for liver tumors using stereotactic MRI-guidance: a prospective phase I trial. Radiother Oncol. 2021;S0167\u20138140(21):06577\u201384.","journal-title":"Radiother Oncol"},{"key":"2114_CR20","doi-asserted-by":"publisher","first-page":"610637","DOI":"10.3389\/fonc.2021.610637","volume":"11","author":"F Weykamp","year":"2021","unstructured":"Weykamp F, Hoegen P, Kl\u00fcter S, et al. Magnetic resonance-guided stereotactic body radiotherapy of liver tumors: initial clinical experience and patient-reported outcomes. Front Oncol. 2021;11:610637.","journal-title":"Front Oncol"},{"issue":"11","key":"2114_CR21","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.clon.2018.08.010","volume":"30","author":"LE Henke","year":"2018","unstructured":"Henke LE, Contreras JA, Green OL, Cai B, Kim H, Roach MC, et al. Magnetic resonance image-guided radiotherapy (MRIgRT): a 4.5-year clinical experience. R Coll Radiol Clin Oncol. 2018;30(11):720\u20137.","journal-title":"R Coll Radiol Clin Oncol"},{"issue":"12","key":"2114_CR22","first-page":"e6457","volume":"11","author":"B Sahin","year":"2019","unstructured":"Sahin B, Zoto Mustafayev T, Gungor G, Aydin G, Yapici B, Atalar B, et al. First 500 fractions delivered with a magnetic resonance-guided radiotherapy system: initial experience. Cureus. 2019;11(12):e6457.","journal-title":"Cureus"},{"key":"2114_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2020.07.003","author":"G G\u00fcng\u00f6r","year":"2020","unstructured":"G\u00fcng\u00f6r G, Serbez \u0130, Temur B, G\u00fcr G, Kayal\u0131lar N, Mustafayev TZ, et al. Time analysis of online adaptive magnetic resonance-guided radiation therapy workflow according to anatomical sites. Pract Radiat Oncol. 2020. https:\/\/doi.org\/10.1016\/j.prro.2020.07.003.","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"2114_CR24","doi-asserted-by":"publisher","first-page":"596","DOI":"10.21037\/gs.2018.11.05","volume":"7","author":"NR Bennion","year":"2018","unstructured":"Bennion NR, Baine M, Granatowicz A, Wahl A. Accelerated partial breast radiotherapy: a review of the literature and future directions. Gland Surg. 2018;7(6):596\u2013610.","journal-title":"Gland Surg"},{"issue":"35","key":"2114_CR25","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1200\/JCO.20.00650","volume":"38","author":"I Meattini","year":"2020","unstructured":"Meattini I, Marrazzo L, Saieva C, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized Phase III APBI-IMRT-Florence trial. J Clin Oncol. 2020;38(35):4175\u201383. https:\/\/doi.org\/10.1200\/JCO.20.00650.","journal-title":"J Clin Oncol"},{"key":"2114_CR26","unstructured":"https:\/\/www.investopedia.com\/investing\/compound-annual-growth-rate-what-you-should-know\/. Accessed 30 Dec 2021."},{"key":"2114_CR27","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S1470-2045(19)30794-6","volume":"21","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Defourny N, Corral J, et al. How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis of reimbursement. Lancet Oncol. 2020;21:e42-54.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2114_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.radonc.2017.11.009","volume":"126","author":"JM Borras","year":"2018","unstructured":"Borras JM, Grau C, Corral J, Wong K, Barton MB, Ferlay J, et al. Estimating the number of fractions by tumour site for European countries in 2012 and 2025: an ESTRO-HERO analysis. Radiother Oncol. 2018;126(2):198\u2013204.","journal-title":"Radiother Oncol"},{"key":"2114_CR29","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.jacr.2018.04.032","volume":"15","author":"TJ Royce","year":"2018","unstructured":"Royce TJ, Qureshi MM, Truong MT. Radiotherapy utilization and fractionation patterns during the first course of cancer treatment in the United States from 2004\u20132014. J Am Coll Radiol. 2018;15:1558\u201364.","journal-title":"J Am Coll Radiol"},{"key":"2114_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.radonc.2015.12.001","volume":"119","author":"K Wong","year":"2016","unstructured":"Wong K, Delaney GP, Barton MB. Evidence-based optimal number of radiotherapy fractions for cancer: a useful tool to estimate radiotherapy demand. Radiother Oncol. 2016;119:145\u20139.","journal-title":"Radiother Oncol"},{"key":"2114_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.radonc.2021.01.003","volume":"157","author":"D Rodin","year":"2021","unstructured":"Rodin D, Tawk B, Mohamad O, et al. Hypofractionated radiotherapy in the real-world setting: an international ESTRO-GIRO survey. Radiother Oncol. 2021;157:32\u20139.","journal-title":"Radiother Oncol"},{"issue":"8","key":"2114_CR32","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3109\/0284186X.2014.1003961","volume":"54","author":"M Dahele","year":"2015","unstructured":"Dahele M, Hatton M, Slotman B, et al. Stereotactic body radiotherapy: a survey of contemporary practice in six selected European countries. Acta Oncol. 2015;54(8):1237\u201341.","journal-title":"Acta Oncol"},{"issue":"1","key":"2114_CR33","doi-asserted-by":"publisher","first-page":"pkx003","DOI":"10.1093\/jncics\/pkx003","volume":"1","author":"JA Holmes","year":"2017","unstructured":"Holmes JA, Zagar TM, Chen R. Adoption of stereotactic body radiotherapy for stage IA non-small cell lung cancer across the United States. JNCI Cancer Spectrum. 2017;1(1):pkx003.","journal-title":"JNCI Cancer Spectrum"},{"key":"2114_CR34","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1148\/radiol.2019190452","volume":"293","author":"AE Campbell-Washburn","year":"2019","unstructured":"Campbell-Washburn AE, Ramasawmy R, Restivo MC, et al. Opportunities in interventional and diagnostic imaging by using high-performance low-field-strength MRI. Radiology. 2019;293:384\u201393. https:\/\/doi.org\/10.1148\/radiol.2019190452.","journal-title":"Radiology"},{"key":"2114_CR35","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1002\/cncr.30034","volume":"122","author":"BR Baker","year":"2016","unstructured":"Baker BR, Basak R, Mohiuddin JJ, et al. Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 to 2012. Cancer. 2016;122:2234\u201341.","journal-title":"Cancer"},{"key":"2114_CR36","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/cncr.31190","volume":"124","author":"BA Mahal","year":"2018","unstructured":"Mahal BA, Chen YW, Sethi RV, et al. Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer. 2018;124:1141\u20139.","journal-title":"Cancer"},{"key":"2114_CR37","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.prro.2017.03.011","volume":"7","author":"WA Stokes","year":"2017","unstructured":"Stokes WA, Kavanagh BD, Raben D, et al. Implementation of hypofractionated prostate radiation therapy in the United States: a National Cancer Database analysis. Pract Radiat Oncol. 2017;7:270\u20138.","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"2114_CR38","doi-asserted-by":"publisher","first-page":"e1920471","DOI":"10.1001\/jamanetworkopen.2019.20471","volume":"3","author":"SS Mahase","year":"2020","unstructured":"Mahase SS, D\u2019Angelo D, Kang J, et al. Trends in the use of stereotactic body radiotherapy for treatment of prostate cancer in the United States. JAMA Netw Open. 2020;3(2):e1920471.","journal-title":"JAMA Netw Open"},{"key":"2114_CR39","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1002\/cncr.30856","volume":"123","author":"SWL De Geus","year":"2017","unstructured":"De Geus SWL, Eskander M, Kasumova GG, et al. Stereotactic body. Radiotherapy for unresected pancreatic cancer: a nationwide review. Cancer. 2017;123:4158\u201367.","journal-title":"Cancer"},{"key":"2114_CR40","unstructured":"de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, et al. First cohort of patients treated on a novel high-field MR-linac within the MOMENTUM Study: initial results from a prospective multi-institutional registry. Int J Radiat Oncol Biol Phys, pp. 1\u20139, 2021."}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02114-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02114-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02114-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T17:08:02Z","timestamp":1661188082000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02114-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2114"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02114-2","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"assertion":[{"value":"24 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BS\u2014department has research agreements with Varian, Elekta and ViewRay; honorarium from ViewRay. MAC\u2014an employee and shareholder in ViewRay, Inc. E\u00d6\u2014ViewRay, Inc. speaker fees; ViewRay advisory board; ViewRay Consulting fees. MK\u2014The author declares that there is no competing interest. JI\u2014Grant from ITOCHU, and Eleka. Consultation fee from HekaBio, AlphaTau, and Palette Science. AT\u2014Department has research support from ViewRay and Qualimedis. JD\u2014Grants from ViewRay, Inc.; Accuray International Sari; Raysearch Laboratories AB; Vision RT Limited; Merck Serono GmbH; Astellas Pharma GmbH; Siemens Healthcare GmbH; Solution Akademie GmbH; Egomed PLC Surrey Research Park; Quintiles GmbH; Pharmaceutical Research Associates GmbH; Boehringer Ingelheim Pharma GmbH&CoKG; PTW-Freiburg Dr. Pychlau GmbH; Nanobiotix S.A.; Accuray Incorporated. RP\u2014The author declares that there is no competing interest. PG\u2014The author declares that there is no competing interest. YH\u2014The author declares that there is no competing interest. NA\u2014research support from: ViewRay, Brainlab. Speaker\u2019s and advisory compensation: ViewRay, Deiobpharm, AstraZeneca. OR\u2014Department has research support from ViewRay and Qualimedis. PC\u2014shareholder GenesisCare; leadership role GenesisCare UK; payment or honoraria from Ipsen, AstraZeneca, and GenesisCare Spain. CB\u2014Grants from ViewRay, BrainLab, Elekta; Payment or honoraria from Elekta, BrainLab, C-RAD, Merck, Merck Sharp & Dohme (MSD), Roche, Astra-Zeneca, Bristol Myers Squibb (BMS); Support for attending meetings and\/or travel from MSD, Roche, Astra-Zeneca, BMS, Merck; Participation in a Data Safety Monitoring Board or Advisory Board\u2014BMS, MSD, Astra-Zeneca. MQ\u2014Department has research support from ViewRay and Qualimedis. BK\u2014The author declares that there is no competing interest. AP\u2014The author declares that there is no competing interest. MvOF\u2014PhD project is sponsored by Varian Medical Systems. YIK\u2014The author declares that there is no competing interest. JHK\u2014ViewRay speaker fee. MF\u2014an employee and shareholder in ViewRay, Inc. VV\u2014department has research support from ViewRay.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}